ClinicalTrials.gg
Not yet recruitingNCT07941089HAND-QCT-RAUpdated Nov 17, 2026

Added Value of HR-pQCT in Detecting Calcium Deposits in Rheumatoid Arthritis

An interventional study of High-Resolution peripheral Quantitative Computed Tomography Imaging in Rheumatoid Arthritis (RA), Calcium Pyrophosphate Deposition Disease and Chondrocalcinosis, sponsored by Istituto Ortopedico Rizzoli. Not yet recruiting at 2 sites in Italy. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Diagnostic

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 188 studies in Arthritis, Rheumatoid with a site in Italy — 19 open to participants now, 29 under way, 3 of them phase 3. Arthritis, Rheumatoid · Italy.

Planned enrollment
110th of 145
140 · median 323
Started
2027
the only one that year
No phase
8 of 188
4 open now
Primary completion
2029-04
later than 22 of 28 live
Registered
189th of 188
by date

Among the 188 studies in Arthritis, Rheumatoid with a site in Italy, this one is the 110th largest by planned enrollment of the 145 interventional ones that give a count, is the only one that started in 2027, is one of 8 with no phase, reaches primary completion later than 22 of the 28 other live ones, and was the 189th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

19 of the 188 studies in Arthritis, Rheumatoid with a site in Italy are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Arthritis, Rheumatoid with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a high-resolution computed tomography scan (HR-pQCT) can detect and describe calcium crystal deposits in the hands and wrists of adults with rheumatoid arthritis (RA). The main questions it aims to answer are:

  • How often does the HR-pQCT scan detect calcium crystal deposits in the hand and wrist joints of people with RA?
  • Can the HR-pQCT scan find calcium deposits that standard tests (x-rays and ultrasound) miss? Researchers will compare scan results from participants with RA to results from participants with known calcium pyrophosphate deposition (CPPD) and participants without joint inflammation.

During a single clinic visit, participants will:

  • Have standard x-rays of their hands and wrists
  • Have a routine ultrasound of their hands and wrists
  • Have an HR-pQCT scan of their wrist and finger joints, which takes about 15 to 20 minutes and uses a very low dose of radiation
Read the detailed description

Calcium pyrophosphate deposition (CPPD) disease is an underdiagnosed crystal arthritis that frequently mimics rheumatoid arthritis (RA) or coexists with it, particularly when presenting as chronic inflammatory polyarthritis involving the wrists and metacarpophalangeal (MCP) joints. Although synovial fluid crystal identification remains the reference standard, aspiration of small hand joints is often technically unfeasible or non-diagnostic. Consequently, diagnosis relies heavily on conventional radiography and musculoskeletal ultrasonography, both of which suffer from recognized limitations in detecting subtle or early calcifications.

High-resolution peripheral quantitative computed tomography (HR-pQCT) provides superior spatial resolution and volumetric bone microarchitecture assessment. This multicenter, cross-sectional pilot study investigates whether HR-pQCT can enhance the detection and structural characterization of CPPD-suggestive calcium deposits within the triangular fibrocartilage complex (TFCC) and 2nd/3rd MCP hyaline cartilage.

To enable combined multi-site analysis, cross-calibration between the two participating tertiary centers (IRCCS Istituto Ortopedico Rizzoli, utilizing a second-generation Scanco XtremeCT II system, and AOUI Verona, utilizing a RAR Medical Devices ArtiCAT cone-beam system) is conducted using the European Forearm Phantom (EFP; QRM AG). Scans follow harmonized volumetric acquisition protocols based on international recommendations (SPECTRA group). All imaging acquisitions (radiographs, ultrasound, and HR-pQCT) are evaluated independently and in a double-blinded manner by trained musculoskeletal radiologists and rheumatologists.

At the patient level, a participant is classified as positive if at least one calcium deposit is detected in any of the examined joints. Because each participant undergoes imaging across multiple anatomical sites (the TFCC of the wrist and the 2nd and 3rd metacarpophalangeal joints of both hands), observations from the same individual are correlated. To account for this within-subject correlation without losing anatomical detail, site-specific analyses will be conducted using mixed-effects models or generalized estimating equations (GEE).

03

Conditions studied

  • Rheumatoid Arthritis (RA)
  • Calcium Pyrophosphate Deposition Disease
  • Chondrocalcinosis

Keywords

  • HR-pQCT
  • CPPD
  • TFCC
  • MCP joints
  • RA
  • CR
  • US
  • Calcium Deposits
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Rheumatoid Arthritis (RA) Cohort:

  • Age ≥ 60 years
  • Diagnosis of Rheumatoid Arthritis according to 2010 ACR/EULAR classification criteria
  • Clinical diagnosis confirmed by an expert rheumatologist
  • Current or past inflammatory involvement of the hand and/or wrist
  • Written obtained

Calcium Pyrophosphate Deposition (CPPD) Cohort:

  • Age ≥ 60 years
  • Established diagnosis of CPPD based on synovial fluid crystal analysis and/or imaging findings compatible with current classification criteria
  • Current or past inflammatory involvement of the hand and/or wrist
  • Written informed consent obtained

Control Cohort (Non-inflammatory Controls):

  • Age ≥ 60 years
  • Outpatient evaluation at one of the participating centers for a condition not suggestive of CPPD, rheumatoid arthritis, erosive osteoarthritis, or other inflammatory joint diseases
  • Clinical indication for conventional radiography of the hand and/or wrist as part of routine clinical practice
  • Absence of past or present hand or wrist joint swelling suggestive of inflammatory arthritis
  • Written informed consent obtained

Exclusion criteria

Exclusion Criteria:

All Cohorts:

  • to CT-based imaging (including the inability to immobilize the hand and wrist during image acquisition)
  • Known causes of secondary CPPD (e.g., hyperparathyroidism, hemochromatosis, hypomagnesemia, hypophosphatasia)
  • Presence of hand/wrist prosthesis or osteosynthesis material interfering with image acquisition
  • Inability to provide written
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Rheumatoid Arthritis (RA) Cohort

    Patients with RA and current or prior hand/wrist involvement (n = 60).

    Device: High-Resolution peripheral Quantitative Computed Tomography Imaging

  • Active comparator
    Healthy / Non-inflammatory Controls

    Subjects undergoing hand/wrist imaging for non-inflammatory conditions (n = 60).

    Device: High-Resolution peripheral Quantitative Computed Tomography Imaging

  • Active comparator
    CPPD Positive Control Cohort

    Patients with proven CPPD disease (n = 20).

    Device: High-Resolution peripheral Quantitative Computed Tomography Imaging

Interventions

  • DeviceHigh-Resolution peripheral Quantitative Computed Tomography Imaging

    High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.

    Also known as: HR-pQCT, Scanco XtremeCT II, RAR Medical Devices ArtiCAT cone-beam

06

What researchers measure

Primary outcomes

  1. Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in rheumatoid arthritis

    Percentage of participants with rheumatoid arthritis with at least one calcium deposit suggestive of CPPD detected by HR-pQCT at the triangular fibrocartilage complex (TFCC) and/or the 2nd-3rd metacarpophalangeal (MCP) joints.

    Time frame: Baseline (single imaging visit)

Secondary outcomes

  1. Proportion of HR-pQCT-positive cases missed by conventional imaging

    Percentage of participants with no CPPD-suggestive calcium deposits on either conventional radiography or ultrasonography who have at least one CPPD-suggestive calcium deposit on HR-pQCT.

    Time frame: Baseline (single imaging visit)

  2. Agreement between conventional radiography and HR-pQCT for CPPD-suggestive calcium deposits

    Cohen's kappa coefficient for agreement between conventional radiography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.

    Time frame: Baseline (single imaging visit)

  3. Agreement between ultrasonography and HR-pQCT for CPPD-suggestive calcium deposits

    Cohen's kappa coefficient for agreement between ultrasonography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.

    Time frame: Baseline (single imaging visit)

  4. Agreement between combined conventional imaging and HR-pQCT for CPPD-suggestive calcium deposits

    Cohen's kappa coefficient for agreement between combined conventional imaging and HR-pQCT. A participant is classified as positive on combined conventional imaging if deposits are detected on radiography, ultrasonography, or both.

    Time frame: Baseline (single imaging visit)

  5. Volume of CPPD-suggestive calcium deposits on HR-pQCT

    Total volume of CPPD-suggestive calcium deposits per participant, measured on HR-pQCT (mm³), in participants with at least one deposit.

    Time frame: Baseline (single imaging visit)

  6. Volumetric density of CPPD-suggestive calcium deposits on HR-pQCT

    Mean volumetric density of CPPD-suggestive calcium deposits (mg HA/cm³), measured on HR-pQCT, in participants with at least one deposit.

    Time frame: Baseline (single imaging visit)

  7. Anatomical distribution of CPPD-suggestive calcium deposits on HR-pQCT

    Percentage of participants with deposits at the TFCC only, at the 2nd-3rd MCP joints only, or at both sites, among participants with at least one deposit on HR-pQCT.

    Time frame: Baseline (single imaging visit)

Other outcomes

  1. Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in seronegative vs seropositive rheumatoid arthritis

    Percentage of participants with at least one CPPD-suggestive calcium deposit on HR-pQCT, reported separately for seronegative participants (RF- and ACPA-negative) and seropositive participants.

    Time frame: Baseline (single imaging visit)

07

Study locations

2 sites
  • IRCCS Istituto Ortopedico Rizzoli - SSD Medicina e Reumatologia
    Bologna, Bologna 40136, Italy
  • Azienda Ospedaliera Universitaria Integrata di Verona - UO di Reumatologia
    Verona, Verona 37134, Italy
08

References and documents

Publications

  • Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-8. doi: 10.1136/ard.2010.138461. PubMed 20699241 ↗
  • Filippou G, Adinolfi A, Cimmino MA, Scire CA, Carta S, Lorenzini S, Santoro P, Sconfienza LM, Bertoldi I, Picerno V, Di Sabatino V, Ferrata P, Galeazzi M, Frediani B. Diagnostic accuracy of ultrasound, conventional radiography and synovial fluid analysis in the diagnosis of calcium pyrophosphate dihydrate crystal deposition disease. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):254-60. Epub 2016 Feb 9. PubMed 26886247 ↗
  • Krekeler M, Baraliakos X, Tsiami S, Braun J. High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. RMD Open. 2022 Jun;8(2):e002383. doi: 10.1136/rmdopen-2022-002383. PubMed 35701012 ↗
  • Tedeschi SK, Becce F, Pascart T, Guermazi A, Budzik JF, Dalbeth N, Filippou G, Iagnocco A, Kohler MJ, Laredo JD, Smith SE, Simeone FJ, Yinh J, Choi H, Abhishek A. Imaging Features of Calcium Pyrophosphate Deposition Disease: Consensus Definitions From an International Multidisciplinary Working Group. Arthritis Care Res (Hoboken). 2023 Apr;75(4):825-834. doi: 10.1002/acr.24898. Epub 2022 Nov 23. PubMed 35439343 ↗
  • Barnabe C, Feehan L; SPECTRA (Study GrouP for XTrEme-CT in RA). High-resolution peripheral quantitative computed tomography imaging protocol for metacarpophalangeal joints in inflammatory arthritis: the SPECTRA collaboration. J Rheumatol. 2012 Jul;39(7):1494-5. doi: 10.3899/jrheum.120218. No abstract available. PubMed 22753808 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Apr 2029, 27 months later.

Of 292 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 27 months is above that.

Counting every sponsor, half of 348 studies reached it within 27 months; a quarter within 13 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 17, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Apr 30, 2029
CompletionEst.
Oct 31, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941089
Collaborators
Azienda Ospedaliera Universitaria Integrata Verona
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Apr 30, 2029 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Jacopo Ciaffi
Contact
jacopo.ciaffi@ior.it
+39 051.6445505

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion